259 related articles for article (PubMed ID: 34743279)
1. ASO Author Reflections: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Tonello M; Sommariva A
Ann Surg Oncol; 2022 Jun; 29(6):3418-3419. PubMed ID: 34743279
[No Abstract] [Full Text] [Related]
2. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Giuffrè G; Donini A; Fugazzola P; Faviana P; Sorrentino L; Scapinello A; Del Bianco P; Sommariva A
Ann Surg Oncol; 2022 Jun; 29(6):3405-3417. PubMed ID: 34783946
[TBL] [Abstract][Full Text] [Related]
3. ASO Author Reflections: Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity Score Analysis.
Tonello M; Sommariva A
Ann Surg Oncol; 2024 Mar; 31(3):2008-2009. PubMed ID: 37851201
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Significance of Primary Tumor Location and Genomic Alterations in Colorectal Peritoneal Metastases and Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy.
Hamed AB; Choudry MH
Ann Surg Oncol; 2023 Jul; 30(7):4471-4472. PubMed ID: 37103724
[No Abstract] [Full Text] [Related]
5. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
Bhullar D; O'Dwyer S; Wilson M; Saunders MP; Kochhar R; Barriuso J; Aziz O
Ann Surg Oncol; 2023 Feb; 30(2):792-801. PubMed ID: 36400886
[TBL] [Abstract][Full Text] [Related]
6. ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Dietz MV; Madsen EVE
Ann Surg Oncol; 2022 Oct; 29(11):6577-6578. PubMed ID: 35486267
[No Abstract] [Full Text] [Related]
7. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes.
Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S
Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754
[TBL] [Abstract][Full Text] [Related]
8. ASO Author Reflections: Addressing Hospital-Based Disparities in Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) and Survival in Patients with Isolated Colorectal Peritoneal Metastases.
van der Ven RGFM; van den Heuvel TBM; Rovers KPB; Nienhuijs SW; van Erning FN; de Hingh IHJT
Ann Surg Oncol; 2024 Jun; 31(6):3787-3788. PubMed ID: 38498087
[No Abstract] [Full Text] [Related]
9. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.
Narasimhan V; Tan S; Kong J; Pham T; Michael M; Ramsay R; Warrier S; Heriot A
Colorectal Dis; 2020 Nov; 22(11):1482-1495. PubMed ID: 32027455
[TBL] [Abstract][Full Text] [Related]
10. RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.
Arjona-Sanchez A; Rodriguez-Ortiz L; Baratti D; Schneider MA; Gutiérrez-Calvo A; García-Fadrique A; Tuynman JB; Cascales-Campos PA; Martín VC; Morales R; Salti GI; Arteaga X; Pacheco D; Alonso-Gomez J; Yalkin O; Villarejo-Campos P; Sanchez-Hidalgo JM; Casado-Adam A; Cosano-Alvarez A; Rufian-Peña S; Briceño J
Ann Surg Oncol; 2019 Aug; 26(8):2595-2604. PubMed ID: 31111351
[TBL] [Abstract][Full Text] [Related]
11. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Where do we stand?
Witmer HDD; Dhiman A; Turaga KK
Cancer; 2023 Feb; 129(4):495-502. PubMed ID: 36527271
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
14. New insights into the unique nature of colorectal cancer peritoneal metastases-rethinking HIPEC.
Ramsay RG; Flood M
Br J Cancer; 2022 Aug; 127(3):377-378. PubMed ID: 35831561
[TBL] [Abstract][Full Text] [Related]
15. ASO Author Reflections: If Once Is Good, Is Twice Just as Good? A critical evaluation of Repeat CRS-HIPEC for Colorectal Peritoneal Metastases.
Laks S; Adileh M; Ben-Yaacov A; Nissan A
Ann Surg Oncol; 2021 Sep; 28(9):5339-5340. PubMed ID: 33604829
[No Abstract] [Full Text] [Related]
16. Prognostic significance of ovarian metastases (macroscopic or microscopic) in patients with colorectal cancer undergoing cytoreduction followed by HIPEC.
Iavazzo C; Spiliotis J
Int J Colorectal Dis; 2020 Jul; 35(7):1335-1336. PubMed ID: 32363478
[No Abstract] [Full Text] [Related]
17. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
18. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
19. Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer.
Jeon Y; Park EJ; Lim JH; Baik SH
World J Surg Oncol; 2019 Dec; 17(1):214. PubMed ID: 31829188
[TBL] [Abstract][Full Text] [Related]
20. [Application and prospect of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal metastasis from colorectal cancer].
Zhou SC; Pei W; Zhou HT; Liang JW; Zhou ZX
Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):73-78. PubMed ID: 35073651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
